Ikramy A. Khalil

3.9k total citations · 1 hit paper
37 papers, 3.3k citations indexed

About

Ikramy A. Khalil is a scholar working on Molecular Biology, Genetics and Immunology. According to data from OpenAlex, Ikramy A. Khalil has authored 37 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 16 papers in Genetics and 7 papers in Immunology. Recurrent topics in Ikramy A. Khalil's work include RNA Interference and Gene Delivery (31 papers), Advanced biosensing and bioanalysis techniques (22 papers) and Virus-based gene therapy research (16 papers). Ikramy A. Khalil is often cited by papers focused on RNA Interference and Gene Delivery (31 papers), Advanced biosensing and bioanalysis techniques (22 papers) and Virus-based gene therapy research (16 papers). Ikramy A. Khalil collaborates with scholars based in Japan, Egypt and United Kingdom. Ikramy A. Khalil's co-authors include Hideyoshi Harashima, Kentaro Kogure, Hidetaka Akita, Shiroh Futaki, Seigo Kimura, Mahmoud A. Younis, Yaser Hosny Ali Elewa, Ayman El‐Sayed, Yusuke Sato and Rie Ito and has published in prestigious journals such as Journal of Biological Chemistry, Biomaterials and Advanced Functional Materials.

In The Last Decade

Ikramy A. Khalil

37 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Uptake Pathways and Subsequent Intracellular Trafficking in Nonviral Gene Delivery

2006 1.0k citations Ikramy A. Khalil, Kentaro Kogure et al. Pharmacological Reviews profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ikramy A. Khalil Japan	27	2.7k	705	646	437	326	37	3.3k
Shaohui Cui China	19	2.5k 0.9×	593 0.8×	537 0.8×	386 0.9×	272 0.8×	28	2.9k
Carsten Rudolph Germany	35	3.2k 1.2×	1.2k 1.7×	548 0.8×	530 1.2×	406 1.2×	70	4.5k
Stephany Y. Tzeng United States	34	2.3k 0.9×	553 0.8×	776 1.2×	859 2.0×	450 1.4×	79	3.5k
Patrick Erbacher France	30	3.3k 1.2×	1.4k 2.0×	424 0.7×	334 0.8×	303 0.9×	53	4.0k
Miriam Breunig Germany	24	2.3k 0.9×	623 0.9×	837 1.3×	691 1.6×	188 0.6×	53	3.4k
Joseph Rosenecker Germany	30	2.6k 1.0×	919 1.3×	366 0.6×	404 0.9×	359 1.1×	52	3.4k
Antoine Kichler France	34	3.6k 1.3×	1.2k 1.8×	453 0.7×	350 0.8×	284 0.9×	106	4.2k
Sean A. Dilliard United States	8	2.2k 0.8×	377 0.5×	452 0.7×	441 1.0×	422 1.3×	9	2.8k
Yuriko Higuchi Japan	28	1.5k 0.5×	346 0.5×	393 0.6×	545 1.2×	310 1.0×	86	2.2k
Mattias Hällbrink Sweden	33	4.2k 1.5×	647 0.9×	457 0.7×	354 0.8×	496 1.5×	59	4.7k

Countries citing papers authored by Ikramy A. Khalil

Since Specialization

Citations

This map shows the geographic impact of Ikramy A. Khalil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ikramy A. Khalil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ikramy A. Khalil more than expected).

Fields of papers citing papers by Ikramy A. Khalil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ikramy A. Khalil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ikramy A. Khalil. The network helps show where Ikramy A. Khalil may publish in the future.

Co-authorship network of co-authors of Ikramy A. Khalil

This figure shows the co-authorship network connecting the top 25 collaborators of Ikramy A. Khalil. A scholar is included among the top collaborators of Ikramy A. Khalil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ikramy A. Khalil. Ikramy A. Khalil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

El‐Tanani, Mohamed, Syed Arman Rabbani, Yahia El‐Tanani, Ismail Matalka, & Ikramy A. Khalil. (2024). Bridging the gap: From petri dish to patient - Advancements in translational drug discovery. Heliyon. 11(1). e41317–e41317. 3 indexed citations

Younis, Mahmoud A., Ikramy A. Khalil, Yaser Hosny Ali Elewa, Yasuhiro Kon, & Hideyoshi Harashima. (2021). Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo. Journal of Controlled Release. 331. 335–349. 90 indexed citations

Khalil, Ikramy A., et al.. (2020). A novel dual-targeted rosiglitazone-loaded nanoparticle for the prevention of diet-induced obesity via the browning of white adipose tissue. Journal of Controlled Release. 329. 665–675. 42 indexed citations

Akita, Hidetaka, Ikramy A. Khalil, Mahmoud M. Abd Elwakil, et al.. (2019). A study of the endocytosis mechanism and transendothelial activity of lung-targeted GALA-modified liposomes. Journal of Controlled Release. 307. 55–63. 36 indexed citations

Younis, Mahmoud A., Ikramy A. Khalil, Mahmoud M. Abd Elwakil, & Hideyoshi Harashima. (2019). A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells. Molecular Pharmaceutics. 16(9). 4031–4044. 53 indexed citations

Kimura, Seigo, Ikramy A. Khalil, Yaser Hosny Ali Elewa, & Hideyoshi Harashima. (2019). Spleen selective enhancement of transfection activities of plasmid DNA driven by octaarginine and an ionizable lipid and its implications for cancer immunization. Journal of Controlled Release. 313. 70–79. 26 indexed citations

Nakamura, Takashi, Yuma Yamada, Yusuke Sato, Ikramy A. Khalil, & Hideyoshi Harashima. (2019). Innovative nanotechnologies for enhancing nucleic acids/gene therapy: Controlling intracellular trafficking to targeted biodistribution. Biomaterials. 218. 119329–119329. 36 indexed citations

Hayashi, Yasuhiro, et al.. (2012). Pretreatment of Hepatocyte Growth Factor Gene Transfer Mediated by Octaarginine Peptide-Modified Nanoparticles Ameliorates LPS/D-Galactosamine-Induced Hepatitis. Nucleic Acid Therapeutics. 22(5). 360–363. 18 indexed citations

Hayashi, Yasuhiro, Jun Yamauchi, Ikramy A. Khalil, et al.. (2011). Cell penetrating peptide-mediated systemic siRNA delivery to the liver. International Journal of Pharmaceutics. 419(1-2). 308–313. 51 indexed citations

10.

Akita, Hidetaka, Ikramy A. Khalil, Rumiko Moriguchi, et al.. (2009). Multi-layered nanoparticles for penetrating the endosome and nuclear membrane via a step-wise membrane fusion process. Biomaterials. 30(15). 2940–2949. 118 indexed citations

11.

Higashi, Tomoko, Ikramy A. Khalil, Kaustabh Kumar Maiti, et al.. (2009). Novel lipidated sorbitol-based molecular transporters for non-viral gene delivery. Journal of Controlled Release. 136(2). 140–147. 20 indexed citations

12.

El‐Sayed, Ayman, Ikramy A. Khalil, Kentaro Kogure, Shiroh Futaki, & Hideyoshi Harashima. (2008). Octaarginine- and Octalysine-modified Nanoparticles Have Different Modes of Endosomal Escape. Journal of Biological Chemistry. 283(34). 23450–23461. 166 indexed citations

13.

Khalil, Ikramy A., Kentaro Kogure, Shiroh Futaki, & Hideyoshi Harashima. (2008). Octaarginine-modified liposomes: Enhanced cellular uptake and controlled intracellular trafficking. International Journal of Pharmaceutics. 354(1-2). 39–48. 90 indexed citations

14.

Khalil, Ikramy A., Kentaro Kogure, Shiroh Futaki, et al.. (2007). Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery. Gene Therapy. 14(8). 682–689. 153 indexed citations

15.

Akita, Hidetaka, et al.. (2006). Cellular uptake and subsequent intracellular trafficking of R8-liposomes introduced at low temperature. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1758(6). 713–720. 56 indexed citations

16.

Khalil, Ikramy A., Kentaro Kogure, Hidetaka Akita, & Hideyoshi Harashima. (2006). Uptake Pathways and Subsequent Intracellular Trafficking in Nonviral Gene Delivery. Pharmacological Reviews. 58(1). 32–45. 1035 indexed citations breakdown →

17.

Khalil, Ikramy A., Kentaro Kogure, Shiroh Futaki, & Hideyoshi Harashima. (2005). High Density of Octaarginine Stimulates Macropinocytosis Leading to Efficient Intracellular Trafficking for Gene Expression. Journal of Biological Chemistry. 281(6). 3544–3551. 334 indexed citations

18.

Mudhakir, Diky, Hidetaka Akita, Ikramy A. Khalil, Shiroh Futaki, & Hideyoshi Harashima. (2005). Pharmacokinetic Analysis of the Tissue Distribution of Octaarginine Modified Liposomes in Mice. Drug Metabolism and Pharmacokinetics. 20(4). 275–281. 25 indexed citations

19.

Khalil, Ikramy A., Shiroh Futaki, Mineo Niwa, et al.. (2004). Mechanism of improved gene transfer by the N-terminal stearylation of octaarginine: enhanced cellular association by hydrophobic core formation. Gene Therapy. 11(7). 636–644. 143 indexed citations

20.

Akita, Hidetaka, Rie Ito, Ikramy A. Khalil, Shiroh Futaki, & Hideyoshi Harashima. (2004). Quantitative Three-Dimensional Analysis of the Intracellular Trafficking of Plasmid DNA Transfected by a Nonviral Gene Delivery System Using Confocal Laser Scanning Microscopy. Molecular Therapy. 9(3). 443–451. 145 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact